- $50+ million in federal funding for ibogaine and related compound research
- Mandated expedited FDA review process for emerging therapies
- Expanded coordination between HHS, VA, and state partners
- Regulatory modernization to align FDA approval with DEA scheduling
- Focus on veterans with PTSD, TBI, and substance use disorder
A Historic Breakthrough
On April 18, 2026, President Donald J. Trump signed an Executive Order that marks a watershed moment for psychedelic medicine in the United States. The directive launches a coordinated federal effort to prioritize ibogaine research, accelerate clinical development, and modernize regulatory pathways for emerging therapies—with a particular focus on America's veterans.
This action represents the culmination of years of advocacy by organizations like Americans for Ibogaine, the national nonprofit that has been central to advancing ibogaine from the margins of policy conversations to a national priority. Through their work educating lawmakers, elevating credible research, and bringing forward lived experience, Americans for Ibogaine helped drive Texas' historic $100 million investment in ibogaine clinical trials and catalyzed the momentum behind this federal action.
What the Executive Order Means
The Executive Order establishes a whole-of-government approach to ibogaine research with several critical components:
Significant Federal Investment: No less than $50 million in federal funding will support research into ibogaine and related compounds, representing one of the largest government commitments to psychedelic medicine research in history.
Expedited Regulatory Pathways: The order mandates expedited FDA review processes, expands coordination across the Department of Health and Human Services and the Department of Veterans Affairs, and establishes federal-state collaboration frameworks to remove barriers to research and care.
Regulatory Modernization: Critically, the order calls for aligning FDA approval processes with DEA scheduling, ensuring that effective treatments can move more quickly to patients once proven safe and effective.
"This is a historic moment for our Veterans and for this country. I have seen firsthand the impact ibogaine can have on our warfighters. For too long, they have been forced to leave the United States to access care. That should never have been the case. Today is a major step toward correcting that." — Rick Perry, Chairman of Americans for Ibogaine and former Texas Governor
Veterans Speak Out
The human impact of this policy shift cannot be overstated. For veterans who have exhausted conventional treatment options, this Executive Order offers new hope.
"Ibogaine freed me from trauma and substance use in a way nothing else ever could, and it made me a better man. The signing of this Executive Order tells our Veterans they have not been forgotten and that real help is finally coming." — Marcus Luttrell, Navy SEAL Veteran, author of Lone Survivor, and Americans for Ibogaine Board Member
Prior to this Executive Order, ibogaine remained classified as a Schedule I substance—a category reserved for drugs defined as having no accepted medical use and high abuse potential. Emerging scientific evidence, including the landmark Stanford study showing 88% PTSD symptom reduction, increasingly calls that classification into question.
Implications for Israel
This federal action in the United States carries profound implications for Israel. With over 85,000 IDF soldiers receiving psychological treatment since October 7, 2023, and projections showing a 180% increase in PTSD cases by 2028, Israel faces a mental health crisis of historic proportions.
The U.S. Executive Order creates momentum that Israel can leverage:
Israel's world-class medical infrastructure, combined with its history of innovative drug policy (as demonstrated by the national medical cannabis program), positions the country to move swiftly on ibogaine research and access. The regulatory and scientific momentum from the United States will accelerate global acceptance of ibogaine as a legitimate therapeutic option.
The Path Forward
Americans for Ibogaine, which helped lay the groundwork for this historic moment, will continue working with federal and state partners, research institutions, and healthcare leaders to advance ibogaine research with urgency and integrity.
For Israel, this Executive Order serves as both a model and a call to action. The era of federal prohibition of psychedelic medicine in America is coming to an end. Israel must ensure its trauma survivors—civilian and military alike—have access to the world's most promising new therapies.
"This began with a small group who refused to accept the status quo and fought to bring ibogaine into the United States healthcare system, growing into a national movement that could not be ignored. We have always believed this was the moonshot of our time." — W. Bryan Hubbard, CEO of Americans for Ibogaine
About Americans for Ibogaine
Americans for Ibogaine is a national 501(c)(3) nonprofit organization dedicated to advancing the medicalization of ibogaine through FDA-approved clinical trials, evidence-based policy, and public education. Learn more at americansforibogaine.org
Sources
- Americans for Ibogaine (2026). Press Release: Americans for Ibogaine Applauds Executive Order Prioritizing Ibogaine Research. americansforibogaine.org
- The White House (2026). Executive Order on Advancing Research and Treatment for Veterans.